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Abstract 
 
Variation in ACE activity affects myogenic differentiation in C2C12 cells. The present 
study investigated the mechanism by which ACE influences the myogenic 
differentiation using the ACE-transduced C2C12 cells. Overexpression of ACE induced 
the down-regulation of myosin heavy chain, a late myogenic marker at 3-5 days after 
induction of differentiation. ACE-transduced cells exhibited the immature myotubes but 
an early myoigenc marker (myogenin) was transiently increased at day 1. In 
ACE-transduced cells, phosphorylation of mTOR and its downstream effector (p70S6K) 
was suppressed at 2-5 day. However, upstream effector of mTOR (Akt) was transiently 
suppressed at day 3. Expression of IGF-II mRNA, which is controlled by mTOR, was 
also down-regulated during the differentiation in ACE-transduced cells. On the other 
hand, the treatment of cells with captopril, an ACE inhibitor, induced up-regulations of 
myosin heavy chain and phosphorylated p70S6K. These results suggest that ACE 
negatively regulates the myotube maturation via impairment of mTOR function. 
 
Key words: ACE; mTOR; IGF-II; differentiation; maturation; myogenesis; C2C12
Introduction  
 
Skeletal muscle exhibits a remarkable capacity to adapt to physiological 
demands such as growth, training, and injury. The processes by which these adaptations 
occur are largely attributed to a small population of cells that are resident in skeletal 
muscle and are referred to as satellite cells, which remain in a quiescence state under 
normal condition [1]. In response to hypertrophic stimuli, the quiescent satellite cells 
activate, proliferate, and fuse with the preexisting muscle fibers, or with each other to 
form the novel muscle fibers [1]. Whereas in atrophied muscle, the number of satellite 
cells is decreased, and its capacities of proliferation and differentiation are 
down-regulated [1]. Thus, satellite cells play important roles in skeletal muscle 
remodeling. Differentiation is one of the events of skeletal muscle remodeling by 
satellite cells, and has been defined in the in vitro system of myoblast cell cultures [2,3]. 
This event consists of myogenin expression, cell cycle withdrawal, phenotypic 
differentiation as marked by contractile expression, and cell fusion to form 
multinucleated myotube [4], and it involves a large number of intracellular and 
extracellular mediators in each step [1]. 
Angiotensin I-converting enzyme (ACE) is a zinc metallopeptidase that 
generates the vasoconstrictor peptide angiotensin II, inactivates the vasodilator peptide 
bradykinin, and traditionally thought to play an important role in control of blood 
pressure through the renin-angotensin system and kallikrein-kinin system [6]. Recently, 
a large number of studies have suggested that ACE is involved in skeletal muscle 
function such as muscle strength and muscle hypertrophy by training [7,8]. Our 
previous study suggested the role of the satellite cells, which mediate the effect of ACE 
activity on skeletal muscle function [5].  
The treatment of differentiating C2C12 cells, a mouse skeletal muscle satellite 
cell-derived cell line, with ACE inhibitor induced the up-regulation of myosin heavy 
chain, and the hypertrophic myotube. On the other hand, overexpression of ACE 
adversely induced the down-regulation of myosin heavy chain [5]. These results 
suggested that the variations of ACE activities affected the differentiation of myoblast to 
myotube. In the present study, we investigated the detailed mechanism by which ACE 
influences the myogenic differentiation using the ACE-transduced C2C12 cells.
Materials and methods 
 
Materials. 
 Captopril, low glucose Dulbecco’s modified Eagle’s medium (DMEM) and mouse 
monoclonal antibody for myosin heavy chain (MY-32) were purchased from Sigma (St. 
Lois, MO). Fetal bovine serum (FBS) was from Hyclone (Logan, UT). Horse serum 
(HS) was from Cosmo-bio (Tokyo, Japan). Mouse monoclonal antibody for myogenin, 
goat polyclonal antibody for β-actin, horseradish peroxidase-conjugated goat 
anti-mouse antibody and horseradish peroxidase-conjugated rabbit anti-goat antibody 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal 
antibodies for phospho-Akt (Ser473), total-Akt, total-p70S6K and phospho-mTOR 
(Ser2448), rabbit monoclonal antibody for phospho-p70S6K (Thr389) (108D2) and 
total-mTOR (7C10), and horseradish peroxidase-conjugated goat anti-rabbit antibody 
were from Cell Signaling Technology (Beverly, MA). 
 
Cell culture. 
 Murine C2C12 cells were generously provided by Dr. Tohru Takemasa (University of 
Tsukuba), and ACE-overexpressed C2C12 cells were generated as previously [5]. Cells 
were maintained in high glucose DMEM containing 10% heat-inactivated FBS and 
antibiotics at 37 °C with 5% CO2. For differentiation, cells were plated at density of 4 × 
105 cells per 60 mm dish coated with 0.1% gelatin. After 24 h, the cells were changed 
into differentiation medium (low glucose DMEM containing 2% HS and antibiotics) 
and the medium was changed every 1 or 2 days. To visualize myotubular structures, 
cells were washed three times in phosphate-buffered saline (PBS) before fixing for 10 
min in ice-cold methanol at –20 °C. Cells were stained by Giemsa solution for 1 h and 
again washed with PBS. 
 
Western blot analysis. 
 Cells were washed twice with ice-cold PBS, and lysed with lysis buffer composed of 
20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 25 
mM NaF, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM dithiothreitol, and protease 
inhibitors (0.57 mM phenylmethylsulfonyl fluoride, 3 μg/ml Leupeptin, 3 μg/ml 
Pepstatin A, and 0.4% Aprotinin). Lysates were incubated on ice for 30 min followed by 
20 min of centrifugation at 14000 × g, and protein concentrations of the supernatants 
obtained were determined by the Bradford method. Each sample (10-15 μg of cell 
protein) was separated on 10% polyacrylamide gel and then transferred to a 
nitrocellulose membrane. The membrane was blocked for 1 h at room temperature with 
5% skim milk in Tris-bufferd saline containing 0.1% Tween 20 (TBST), and then 
incubated with primary antibodies overnight at 4 °C. The membranes were washed with 
TBST and further incubated with horseradish peroxidase-conjugated secondary 
antibodies for 1 h at room temperature. After washed with TBST, immunocomplexes 
were visualized on X-ray film by chemiluminescence according to manufacture’s 
instructions (GE Healthcare, Piscataway, NJ). Band intensities of immunoblots were 
assessed by using ImageJ (National Institute of Health, Bethesda, MD). 
 Reverse transcription-Polymerase chain reaction (RT-PCR). 
 Cells were washed twice with ice-cold PBS, and total RNAs were extracted using 
RNA-Bee (Tel-test, Friendswood, TX). DNase I-treated RNAs were reverse transcribed 
using TaKaRa RNA PCR kit according to manufacture’s instruction (TaKaRa-Bio, Otsu, 
Japan). The cDNA was diluted in a 1 : 4  ratio, and 2 μl was used for PCR. The 
primers for IGF-II used were: forward 5’-TCAAGCCGTGCCAACCGTCGC-3’; 
reverse 5’-CTCCGAAGAGGCTCCCCCGTG-3’. The primers for GAPDH (forward 
5’-GTGGCAAAGTGGAGATTGTTGCC-3’; reverse 
5’-GATGATGACCCGTTTGGCTTC-3’) were used as an internal control. Each PCR 
regime involved a 94 °C, 5 min initial denaturation step followed by either 25 cycle 
(GAPDH) or 35 cycle (IGF-II) at 94 °C for 1 min, 60 °C for 1 min, 72 °C for 1 min, 
followed by a final amplification step of 5 min at 72 °C. The PCR products were 
separated by electrophoresis on 2% agarose gel.  
 
Statistical analysis. 
 Data are expressed as means ± SD. Comparisons between study groups were made 
using unpaired t-tests, with a P value of < 0.05 being considered statistically significant. 
Results 
 
Overexpression of ACE suppresses the myogenesis by the impairment of myotube 
maturation. 
 Previously, we had produced the ACE-overexpressed C2C12 cells in order to 
investigate the effect of increase in cellular ACE activity on the myogenic 
differentiation. In ACE-transduced cells, myosin heavy chain (MyHC) was 
down-regulated when compared with control cells [5]. Similar to the previous results, 
the ACE-transduced cells contained less MyHC at day 3 and the suppressed level of 
MyHC was maintained for up to day 5 after the induction of differentiation compared 
with the control cells (Fig. 1A). Unexpectedly, the expression of myogenin, the early 
myogenic marker, was up-regulated in the ACE-transduced cells at day 1 (Fig. 1B), 
suggesting that the overexpression of ACE did not suppress the initiation of myogenic 
differentiation. In morphological observation, the control cells exhibited a large number 
of thickened and branched myotubes with clustered nuclei at day 5 (Fig. 1C, a), while 
the sizes of myotubes were smaller, and the fusions of cells to form thickened myotubes 
were less identified in the ACE-tranduced cells (Fig. 1C, b). Collectively, these results 
suggest that the overexpression of ACE does not suppress the beginning of 
differentiation program, however, the processes of further fusion and protein synthesis 
that gives rise to mature myotube size are impaired in these cells. 
 
Overexpression of ACE suppresses the mTOR signaling and the expression of IGF-II. 
 To investigate the mechanism of the down-regulation of MyHC in ACE-overexpressed 
C2C12 cells, we focused on the signaling molecules of Akt and mammalian target of 
rapamycin (mTOR) required for the skeletal muscle development, and examined the 
phosphorylation of these signaling molecules. Although significant suppression in 
phosphorylation of Akt on Ser473 in the ACE-transduced cells was observed only at day 
3 (Fig. 2A), decreased phosphorylation of Ser2448 in mTOR, considered as a 
downstream effecter for Akt, was already identified at day 2 and remained for up to day 
5 (Fig. 2B). Phophorylation of ribosomal protein S6 kinase (p70S6K) on Thr389, 
required as a downstream effector of mTOR, was suppressed from day 2 to day 5 in 
ACE-overexpressed cells (Fig. 2C). These results suggest that the down-regulation of 
MyHC by the overexpression of ACE was due to the impairment of mTOR signaling, 
but Akt was unlikely to be involved in this process. As insulin-like growth factor II 
(IGF-II) transcription in skeletal myogenesis is controlled by mTOR independent of its 
kinase activity [9], the present study investigated whether the impairment of mTOR 
activation affected the expression of IGF-II mRNA during the myogenic differentiation. 
In semiquantitative RT-PCR analysis, the decrease in the expression levels of IGF-II 
mRNA were clearly identified from day 2 to day 5 in the ACE-transduced cells 
compared with the control cells (Fig. 2D), suggesting that IGF-II mRNA expression was 
controlled by ACE via the regulation of mTOR activity. 
 
ACE inhibitor induces the acceleration of myogenesis by the activation of mTOR 
signaling. 
 Previously, we demonstrated that the decrease in extracellular ACE activity by 
captopril, an ACE inhibitor, induced the up-regulation of MyHC in the myogenic 
differentiation [5]. To confirm that ACE activity affect myogenic differentiation through 
mTOR signaling, p70S6K phosphorylation and IGF-II mRNA expression was examined 
in C2C12 cells treated with captopril. Similar to the previous results, treatment with 
1000 μM captopril induced the up-regulation of MyHC compared with non-treatment 
(Fig. 3A). Furthermore, the increased levels of p70S6K phophorylation (Fig. 3A) and 
IGF-II mRNA expression (Fig. 3B) were also observed. These results suggest that 
mTOR signaling also plays a role when myogenic differentiation is stimulated by ACE 
inhibitor.
Discussion 
 
The present study demonstrated that overexpression of ACE suppressed 
myogenic differentiation. MyHC was down-regulated and maturation of myotube was 
impaired in ACE-overexpressed C2C12 cells. Furthermore, suppression of myogenic 
differentiation by ACE was accompanied with decreased mTOR signaling. mTOR is a 
large protein with Ser/Thr kinase activity, which regulates mammalian cell growth and 
proliferation by mediating signal transduction of multiple signaling [10]. 
Phosphorylation of Ser2448 on mTOR has been suggested to play a key role in 
regulating mTOR function [11]. Decreased level of phosphorylation on Ser2448 of 
mTOR in ACE-transduced cells indicates the impairment of signal transduction through 
mTOR. Although we could not directly determine the kinase activity of mTOR, 
decreased level of p70S6K phophorylation could be regarded as the suppressed kinase 
activity of mTOR in ACE-transduced cells. This takes into consideration that mTOR 
directly phosphorylates p70S6K on Thr389 [12]. Previous studies have shown that 
mTOR signaling plays essential roles in myogenic differentiation and skeletal muscle 
hypertrophy [13-17], and the myogenic differentiation is thought to consist of two 
stages. It begins as formation of nascent myotubes by myoblast-myoblast fusion, and 
maturation of myotubes by further fusion and increase in protein synthesis follows. The 
formation of mature myotubes requires the kinase activity of mTOR and a previous 
study has shown that C2C12 cells supported by a kinase-inactive mTOR form nascent 
myotubes, but not mature myotubes [18]. Consistent with the proposed role of mTOR in 
myogenic differentiation, myotubes of ACE-transduced cells in the present study 
exhibited immature phenotyoe i.e. the size of myotubes was smaller and the number of 
nuclei per myotube was decreased. Therefore, the present findings suggest that gain of 
ACE activity impairs mTOR signaling to suppress myogenic differentiation in 
ACE-overexpressed C2C12 cells.  
Interestingly, the expression of myogenin was transiently enhanced at day 1 in 
ACE-overexpressed cells, while the changes in phosphorylation of mTOR and p70S6K 
were not significant. The down-regulations of these phosphorylated proteins became 
significant from day 2, when myogenin expression reached the abundant level. These 
temporal relations imply distinct functions of ACE to stimulate initiation of 
differentiation, independent of mTOR signaling, and to inhibit myotube maturation 
through mTOR signaling. 
Autocrine actions of IGF-II are suggested to be important for the myogenic 
differentiation of satellite cells including C2C12 cells in culture [19,20]. Furthermore, 
recent study has shown that the autocrine IGF-II transcription required for skeletal 
myocyte differentiation is regulated by mTOR activity, which is independent of its 
kinase activity [8]. In our study, the decrease in expression of IGF-II mRNA by the 
overexpression of ACE was clearly identified from day 2, when decreased level of 
phophorylation of mTOR was also observed, suggesting that the expression of IGF-II 
mRNA was influenced by the level of mTOR activation. Taken together, these results 
suggest that the effect of ACE on the myogenic differentiation involves the changes in 
mTOR signaling and mTOR-induced IGF-II functions.  
In the present study, the phoshorylation of Ser2448 in mTOR was suppressed 
in ACE-transduced cells. Although it has been shown that Akt phosphorylates this site 
[11,21], we did not identify the parallel decrease in the level of phophorylation of Akt 
and mTOR in the ACE-transduced cells. Therefore, we speculated that the 
overexpression of ACE targeted the impairment of mTOR activity, and Akt was unlikely 
to be involved in the regulation of mTOR activity by ACE. Reduction of Akt 
phosporylation in ACE-transduced cells became statistically significant at day 3, when 
expression of IGF-II mRNA in control cells appeared to reach the maximal level and it 
was suppressed by ACE overexpression. Since Akt is stimulated, i.e. phosphorylated, by 
IGF and this pathway plays a critical role for IGF’s myogenic signaling [9], one 
possible explanation for the transient suppression of Akt phosphorylation in 
ACE–transduced cells on day 3 is that Akt activity is affected by the action of mTOR 
through changes in IGF-II expression.  
The mechanism by which ACE suppressed the activity of mTOR remains 
unclear. However, previous studies have reported that angiotensin II, generated by ACE, 
induces muscle protein catabolism through the ubiquitin-proteasome proteolytic 
pathway [22,23], and that bradykinin, degraded by ACE, is involved in glucose uptake 
in skeletal muscle [24,25]. A large number of studies have shown that the activity of 
mTOR is regulated by nutrients, growth factors, and cellular metabolism [10]. 
Furthermore, recent study has indicated that mTOR forms a complex with raptor, the 
regulatory associated protein of mTOR, in response to the nutrient-dependent signal, 
and that mTOR/raptor phosphorylates p70S6K on Thr389 [12]. On the other hand, the 
signals of growth factors and insulin are thought to mediate the phosphorylation of Akt 
on Ser473 through a complex of mTOR with rictor, instead of raptor [12]. Possibility 
that nutrient and growth factor signals require different partner of mTOR suggests the 
reason why effect of ACE overexpression on Akt phophorylation was different from that 
of mTOR and p70S6K. The present study suggests that ACE affects the availability of 
nutrients leading to the change in the activity of mTOR. Further study to elucidate our 
hypothesis concerning the relationship between the control of nutrients by ACE and 
mTOR activity is required. 
In conclusion, the present study demonstrates that variations in ACE activities 
affect myogenic differentiation via mTOR signaling pathway. Although ACE may 
possibly cause the changes in nutrient availability to affect mTOR activity, detailed 
mechanism remains unclear and to be elucidated. These studies may shed light on the 
novel role of ACE in the skeletal muscle.
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Figure legends 
 
Fig. 1.  Overexpression of ACE suppresses the myogenic differentiation by the 
impairment of myotube maturation. Control C2C12 cells (C2C12-control or C) and 
ACE-transduced cells (C2C12-ACE or A) were cultured in differentiation medium 
(DM). Each DM was changed at days 1 and 3 after induction of differentiation, and cell 
lysates were harvested. Western blot analysis of cell lysates was performed to determine 
the expression levels of MyHC (A) and myogenin (B). Representative blots pattern was 
shown. The results were expressed as relative values to β-actin expression, and means 
of four different cultures. Black and white bars represent C2C12-ACE and 
C2C12-control cells, respectively. *P < 0.05, **P < 0.01 versus C2C12-control. 
Morphological analyses of both C2C12-control (a) and C2C12-ACE (b) myotubes were 
performed with Giemsa staining at day 5 after induction of differentiation (C). Scale 
bars, 200 μm. 
 
Fig. 2.  Overexpression of ACE suppresses the mTOR signaling and the expression of 
IGF-II mRNA. Control C2C12 cells (C2C12-control or C) and ACE-transduced cells 
(C2C12-ACE or A) were cultured in DM. Each DM was changed at days 1 and 3 after 
induction of differentiation, and cell lysates and total RNAs were harvested. Western 
blot analysis of cell lysates was performed to determine the phosphorylation (depicted 
as “p-“) levels of Akt (Ser473) (A), mTOR (Ser2448) (B) and p70S6K (Thr389) (C). 
Representative blots pattern was shown. The results were expressed as relative values to 
each total protein (depicted as “t-“) expression, and means of four different cultures. 
Black and white bars represent C2C12-ACE and C2C12-control cells, respectively. *P 
< 0.05, **P < 0.01 versus C2C12-control. RT-PCR analysis of RNAs was performed to 
determine the expression level of IGF-II mRNA. The bands of GAPDH were shown as 
internal controls (D). 
 
Fig. 3.  ACE inhibitor induces the acceleration of myogenic differentiation by the 
activation of mTOR signaling. C2C12 cells were cultured in either DM alone (-) or with 
1000 μM captopril (+). Each DM was changed at days 1 and 3 after induction of 
differentiation, and cell lysates and total RNAs were harvested. Western blot analysis 
was performed to determine the levels of MyHC expression and p70S6K (Thr389) 
phosphorylation (p-p70S6K) (A). The blots of total p70S6K (t-p70S6K) and β-actin 
were shown as internal controls. RT-PCR analysis of RNAs was performed to determine 
the expression level of IGF-II mRNA. The bands of GAPDH were shown as internal 
controls (B). 
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